Good news and bad news on the second year of the presidential cycle. Outlook Presidential cycle playbook: ‘Mid-term mayhem’ and a Q4 rally?
Biotech stocks tend to outperform in times of economic expansion. Strategies Why I added Amgen and Celgene to my portfolio
Lower energy costs are boosting corporate cash flows. Strategies On the hunt for cash-spinning companies with a competitive edge
Market choppiness will be the norm not exception. Strategies Get ready for more stock market volatility
Recent data shows fund investors are fleeing stocks and rushing into bonds. Strategies Nervous Nellies: Record bond flows reveal fragile investor sentiment
Commentary from Spark Capital general partner and Covestor board member Todd Dagres. Outlook Online investing can transform wealth management
Emerging markets have given investors nothing but pain. Outlook Picking through the wreckage of emerging markets
Even with a new CEO, Microsoft still seems like a losing bet. Strategies Why it’s time to sell Microsoft
Volatility is creeping back into the market in early 2014 after a long slumber. Outlook Risk protection back in focus as volatility picks up
My portfolio felt the broader declines in consumer stocks. Strategies Tough times for consumer stocks
A correction looks probable, but long-term outlook is strong. Strategies Four reasons a stock market correction is likely
Sizemore Global Macro portfolio manager Charles Sizemore on FOX Business. Strategies Hot money exodus, deficits drive emerging market sell-off: Sizemore
